Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Piraeus – page 19

1 004 clinical trials in Piraeus, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Piraeus at a glance
1 004
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 004 trials in Piraeus

Open in trial search

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Long-term safety and effectiveness study of CYB003 (deupsilocin besilate) with optional additional doses for people with Major Depressive Disorder

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deupsilocin besilate
  • Sponsor:Cybin IRL Limited

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Neoplasm

Recruiting

Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Graves' disease

Recruiting

Study on the Effects and Safety of Rilzabrutinib for Adults with Graves' Disease

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Effectiveness of Macrogol 3350 With Electrolytes and Sodium Picosulfate/Magnesium Citrate Combination for Bowel Preparation in Patients With Inadequate Previous Colonoscopy Preparation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Macrogol 3350
  • Sponsor:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Replimune Inc.

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Piraeus

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, particularly in non-small cell lung cancer and novel therapeutic combinations. Studies include investigations of targeted therapies and immunotherapy approaches.

  • Lung Cancer Therapies
  • Melanoma Treatments
  • Renal Cell Carcinoma

Innovative research combining standard treatments with new therapeutic agents to improve patient outcomes.

02 Cardiovascular Studies

Research initiatives targeting heart failure prevention and stroke prevention in patients with atrial fibrillation. Studies evaluate new therapeutic approaches for managing cardiovascular risks.

  • Heart Failure Prevention
  • Stroke Prevention
  • Hypertension Management

Trials focusing on both preventive measures and treatment of established cardiovascular conditions.

03 Hematology Research

Clinical investigations in multiple myeloma and related blood disorders, exploring combination therapies and novel treatment approaches for patients with various blood-related conditions.

  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Blood Disorders

Studies examining innovative therapeutic combinations for improved patient outcomes.

04 Inflammatory Conditions

Research focusing on treating Crohn's Disease and other inflammatory conditions, evaluating new therapeutic options and combination treatments for better disease management.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Therapies

Studies aimed at improving treatment outcomes in chronic inflammatory diseases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.